Dual Tuned Head Array for MRI/MRS of the Human Brain

描述（由申请人提供）：长期目标是提高人脑磁共振（MR）检查的质量。具体而言，将开发能够同时操作的发射/接收双调谐磷-质子（31 P-1H）头部线圈阵列，以允许在一个临床环境中进行高分辨率质子MR成像、质子MR光谱和质子去耦磷光谱。第一阶段将支持开发1.5吨体积磷和质子，主动可解调发射线圈和多通道磷接收阵列。所提出的双调谐头阵列将在1.57的Phantom上构建和系统验证。应与可比市售器械进行比较，以评价信噪比和均匀性。第二阶段将支持设计优化，然后进行志愿者评估，以在1.5T下改善大脑的磷光谱质量。质子接收阵列将包括在内，“真正的”双调谐磷质子发射/接收头阵列将扩展到3 T。计划设计和开发7 T的定制器械。原型将在体模上进行系统验证，并在人体评价之前与现有线圈进行比较（根据当地IRB）。此外，第2阶段将涉及使器械适应三大MRI OEM（GE、Siemens、Philips）。潜在的研究和临床应用包括对患有神经退行性疾病的患者进行广泛的功能、结构和生化检查，如中风、癫痫和阿尔茨海默病、癌症、神经精神疾病如精神分裂症和艾滋病等。所有这些都将转化为改善的图像质量和在一个患者环境中对成人大脑的x-核的光谱表示，这将有助于诊断。我们认为这将给人类带来重大利益。

DESCRIPTION (provided by applicant): A long term goal is to improve the quality of magnetic resonance (MR) examinations of the human brain. Specifically, transmit/receive dual-tuned phosphorous-proton (31P-1H) head coil arrays capable of simultaneous operation will be developed to permit high-resolution proton MR imaging, proton MR spectroscopy and proton decoupled phosphorous spectroscopy in one clinical setting. Phase I will support development of 1.5T volume phosphorous and proton, actively detuneable transmit coils and multiple channel phosphorous receive array. The proposed dual tuned head array will be built and systematically verified on phantoms at 1.57. Comparisons to the comparable commercial devices to evaluate signal-to-noise and uniformity shall be made. Phase II will support design optimizations followed by volunteer evaluations to achieve improved phosphorous spectral quality over the brain at 1.5T. Proton receive arrays will be included and the "true" dual tuned Phosphorous-Proton transmit/receive head arrays will be extended to 3T. Design and development of custom devices for 7T is planned. Prototypes will be systematically verified on phantoms and compared to existing coils prior to human evaluations (under local IRB). In addition, Phase 2 will involve adaptating the devices to the big three (GE, Siemens, Philips) MRI OEMs. Potential research and clinical use include broad-based functional, structural and biochemical examinations of patients with neurodegenerative disease, such as stroke, epilepsy and alzheimers, cancer, neuropsychiatric diseases such as schizophrenia and AIDS etc. All this will translate in to improved image quality and spectroscopic representation of the x-nucleus over the adult brain in one patient setting, which will aid diagnosis. This we believe will be of a substantial benefit to mankind.